Alerts will be sent to your verified email
Verify Email
GLENMARK
|
Glenmark Pharma
|
Aurobindo Pharma
|
Glaxosmithkline Phar
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
3.99 % | 12.72 % | 40.73 % |
|
5yr Avg Net Profit Margin
|
2.85 % | 12.5 % | 24.91 % |
|
Price to Book
|
6.15 | 1.82 | 24.35 |
|
P/E
|
72.2 | 17.56 | 50.0 |
|
5yr Avg Cash Conversion Cycle
|
-150.94 Days | -46.37 Days | -107.65 Days |
|
5yr Average Interest Coverage Ratio
|
4.25 | 43.54 | 479.64 |
|
5yr Avg ROCE
|
17.54 % | 15.27 % | 44.44 % |
|
5yr Avg Operating Profit Margin
|
15.96 % | 19.22 % | 25.23 % |
|
5 yr average Debt to Equity
|
0.38 | 0.19 | 0.0 |
|
5yr CAGR Net Profit
|
1.54 % | -8.16 % | 20.96 % |
|
5yr Average Return on Assets
|
2.09 % | 8.64 % | 21.84 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
46.65 % | 51.82 % | 75.0 % |
|
Share Pledged by Promoters
|
0.0 | 17.08 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -0.01 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
9.74 % | 9.14 % | 1.11 % |
|
Glenmark Pharma
|
Aurobindo Pharma
|
Glaxosmithkline Phar
|
|---|